Drug-provoked psoriasis: Is it drug induced or drug aggravated? understanding pathophysiology and clinical relevance

Journal of Clinical and Aesthetic Dermatology

Volumn 3, Issue 1, 2010, Pages 32-38

  Kim, Grace K ^a   del Rosso, James Q ^a,b  

^a Mohave Skin and Cancer Clinics   (United States)

^b VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG INDUCED PSORIASIS; ERYTHRODERMA; PATHOPHYSIOLOGY; PSORIASIS; RISK FACTOR; SYMPTOM;

EID: 77954258091     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121-128.
2. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15:16-17.
3. Zahl V, Gerdes S, Mrowietz U. Co-medication in patients with severe psoriasis: first results of a retrospective analysis in 1203 hospitalized patients in Germany. Presented at: the 4th International Congress-The Royal College of Physicians; December 1-3, 2005; London, England.
4. Tsankov N, Irena A, Kasandjieva J. Drug-induced psoriasis: recognition and management. Am J Clin Dermatol. 2000;1:159-165.
5. O'Brian M, Koo J. The mechanism of lithium and beta-blocker agents in inducing and exacerbating psoriasis. J Drugs Dermatol. 2006;5:426-433.
6. Sehgal V, Dogra S, Srivastava G, et al. Psoriasiform dermatoses. Indian J Dermatol Venereol Leprol. 2008;74: 94-99.
7. Weedon D, Strutton G. Psoriasiform tissue reactions. In: Weedon D, ed. Skin Pathology. 2nd ed. New York, NY: Churchill Livingstone; 2002:76-79.
8. Ackerman AB. A method of pattern analysis. In: Histologic Diagnosis of Inflammatory Skin Disease. Philadelphia, Pa: Lea and Febiger; 1978:124-126.
9. Mihm MC. Psoriasiform dermatitis. In: Hood AF, Kwan TH, Mihm MC, et al, eds. Primer of Dermatopathology. Boston, Mass.: Little Brown; 1993:102-106.
10. Smotter BR. Psoriasiform dermatitis. In: Pathology of the Skin. Farmer ER, Hood AF, eds. 1st ed. New York, NY: McGraw Hill; 2000:170-174.
11. Lionel F, Baker B. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25:606-615.
12. Assem ESK, Banks RA. Practolol induced drug eruptions. Proc R Soc Med. 1973;66:179-181.
13. Halevy S, Livni E. Psoriasis and psoriasiform eruptions associated with propranolol-the role of an immunological mechanism. Arch Dermatol Res. 1991;238:472-473.
14. Raftery EB, Denman AM. Systemic lupus erythematosus syndrome induced by practolol. BMJ. 1973;2:452-455.
15. Heng MC, Heng MK. Beta-adrenoceptor antagonist-induced psoriasiform eruption. Clinical and pathogenetic aspects. Int J Dermatol. 1988; 27(9):619-627.
16. Ockenfels HM, Nussbaum G, Schultewolter T, et al. Tyrosine phosphorylation in psoriasis T cells is modified by drugs that induce or improve psoriasis. Dermatology. 1995;191: 217-225.
17. Jenson H, Mikkelsen I, Wadskov F, et al. Cutaneous reactions to propranolol (Inderal). Acta Med Scad. 1976;199:363-367.
18. Steinkraus V, Steinfath M, Mensing H. Beta-adrenergic blocking drugs and psoriasis. J Am Acad Dermatol. 1992;27:266-267.
19. Halevy S, Livni E. Beta-adrenergic blocking drugs and psoriasis: the role of an immunologic mechanism. J Am Acad Dermatol. 1993;29:504-505.
20. Halevy S, Livni E. Psoriasis and psoriasiform eruptions associated with propranolol-the role of an immunologic mechanism. Arch Dermatol Res. 1991;283:472-473.
21. Tsankov N, Pramatarov K, Kamarachev J. Psoriasis placat, die unter der Einwirkung der beta blocker in eine psoriasis. Dtsch Dermatologe. 1992;40:1702-1706.
22. Hu CH, Miller CM, Pepperkorn R, et al. Generalized pustular psoriasis provoked by propranolol. Arch Dermatol. 1985;121:1326-1327.
23. Coignet M, Sayag J. Collyre beta bloquant et psoriasis. Dermatology. 1990;9:552.
24. Puig L, Goni FJ, Roque AM, et al. Psoriasis induced by ophthalmic timolol preparations. Am J Ophthalmol. 1989;108:445-446.
25. Brauchli YB, Jick SS, Meier C. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol. 2008;158:1299-1307.
26. Waqar S, Sarkar P. Exacerbation of psoriasis with beta blocker therapy. CMAJ. 2009;181:1-2.
27. Carter TN. The relationship of lithium carbonate to psoriasis. Psychosomatics. 1972;13(5):325-327.
28. Voorhees JJ, Marcelo CL, Duell EA. Cyclic AMP, cyclic GMP and clucocorticoids as potential metabolic regulators of epidermal proliferation and differentiation. J Invest Dermatol. 1975;65(1):179-190.
29. Bloomfield FJ, Young MM. Enhanced release of inflammatory mediators from lithium-stimulated neutrophils in psoriasis. Br J Dermatol. 1983;109(1)9-13.
30. Di Giovanna JJ, Aoyagai T, Taylor RT. Inhibition of epidermal adenyl cyclase by lithium carbonate. J Invest Dermatol. 1981;76:759-763.
31. Beyaert R, Schulze-Osthoff K, Van Roy F. Synergistic induction of interleukin-6 by tumor necrosis factor and lithium chloride in mice: possible role in the triggering and exacerbation of psoriasis by lithium treatment. Eur J Immunol. 1992;22:218-224.
32. Hwang SM, Ahn SK, Menon GK, et al. Basis of occlusive therapy in psoriasis: correcting defects in permeability barrier and calcium gradient. Int J Dermatol. 2001;40(3):223-231.
33. Odagaki Y, Koyama Y, Yamashita I. Lithium and serotonergic neural transmission: a review of pharmacological and biochemical aspects in animal studies. Lithium. 1992;100: 3-12.
34. Hamlock C, Rosenthal JS, Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother. 1992;26:211-212.
35. Gill R, Mohammed R, Badyal R, et al. High resolution structure of myo-inositol monophosphatase, the putative taret of lithium therapy. Acta Crystallogr D Biol Crystallogr. 2005;61:545-555.
36. Jafferany M. Lithium and psoriasis: what primary care and family physicians should know. Prim Care Companion. J Clin Psychiatry. 2008;10:435-439.
37. Abel EA, DiCicco LM, Orenberg EK, et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol. 1986;15: 1007-1022.
38. Hanada K, Tasaki M, Hashimoto I, et al. Development of psoriasis-like syndrome following lithium therapy. Biol Trace Elem Res. 1978;14:169-177.
39. Sarantidis D, Waters B. A review and controlled study of cutaneous conditions associated with lithium carbonate. Br J Psychiatry. 1983;143:42-50.
40. Skoven I, Thormann J. Lithium compound treatment and psoriasis. Arch Dermatol. 1979;115:1185-1187.
41. Bakker JB, Pepplinkhuizen L. More about the relationship of lithium to psoriasis. Psychosomatics. 1976;17:143-146.
42. Allan SJR, Kavanagh GM, Herd RM, Savin JA. The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial. Br J Dermatol. 2004;150:966-969.
43. Grisaru N, Blemaker RH. Ltihium dosage and inositol levels. Br J Psychiatry. 1994;164(1):133-134.
44. Akkerhuis G, Nolen W. Lithium associated psoriasis and omega-3 fatty acids. Am J Psychiatry. 2003;160:7.
45. Watchter T, Murach WM, Brocker EB, et al. Recalcitrant lithium-induced psoriasis in a suicidal patient alleviated by tumor necrosis factor-alpha inhibition. Br J Dermatol. 2007;157(3):627-629.
46. Wendling D, Blablanc J, Briancon D, et al. Onset or exacerbation of cutaneous psoriasis during TNF alpha antagonist therapy. Joint Bone Spine. 2008;75:315-318.
47. Selmanowitz VJ. Lithium, leukocytes and lesions. Clin Dermatol. 1986;4(1):170-175.
48. Alvarez WA, Freinhar JP. Direct evidence for lithium-induced psoriasis syndrome. Int J Psychosom. 1984;31:21-22.
49. Evans DL, Martin W. Lithium carbonate and psoriasis. Am J Psychiatry. 1979;136:1326-1327.
50. Skoven I, Thormann J. Lithium compound treatment and psoriasis. Arch Dermatol. 1979;115:1185-1187.
51. Wolf R, Schiavo AL. Is transglutaminase the mediator between antimalarial drugs and psoriasis. Int J Dermatol. 1997;36:10-13.
52. Slagel GA, James WD. Plaquentil induced erythroderma. J Am Acad Dermatol. 1985;12:857-862.
53. Baker H. The influence of chloroquine and related drugs on psoriasis and kertoderma blenorrhagium. Br J Dermatol. 1966;78:161-166.
54. Friedman SS. Pustular psoriasis associated with hydroxyl chloroquine. J Am Acad Dermatol. 1987;16:1256-1257.
55. Kufik EG. Effect of anti-malarial drugs on psoriasis. Cutis. 1980;26:153-155.
56. Bessis D, Moles JP, Basset-Seguin N, et al. Differential expression of a human endogenous retrovirus E transmembrane envelope glycoprotein in normal, psoriatic and atopic dermatitis human skin. Br J Dermatol. 2004;151: 737-745.
57. Trnavsky K, Zbojanova M, Vloek F. Antimalarials in psoriatic arthritis. J Rheumatol. 1983;10:833.
58. Botev-Slatkov N, Tsankov N, Tonev S, et al. Drug therapy deteriorates the course of psoriasis. Presented at: 17th World Congress of Dermatology, Part II; West Berlin: Springer; 1987:216.
59. Counis R, Koumanov K, Ranlin J, et al. Intepretation du role antilipolytique de la tetracycline. Inhibition de l'adenylate cyclase in vitro. Eur J Biochem. 1973;37:244-247.
60. Forster S, Ilderton E, Summerly R, et al. The level of phospholipase A2 activity is raised in uninvolved epidermis of psoriasis. Br J Dermatol. 1983;108:103-105.
61. Boothe JH. The tetracyclines. In: Hlavka JJ, ed. Handbook of Experimental Pharmacology. Vol 78. The Tetracyclines. Berlin: Springer-Verlag; 1985:451.
62. Wright AL, Colver GB. Tetracyclines-how safe are they? Clin Exper Dermatol. 1988;13:57-61.
63. Powles AV, Baker BS, Rutman AJ, et al. Epidermal rupture is the initiating factor for the Koebner response in psoriasis. Acta Derm Venereol. 1990;70:35-38.
64. Katz M, Seidenbaum M, Weinrauch L. Penicillin-induced generalized pustular psoriasis. J Am Acad Dermatol. 1987;17:918-920.
65. Sidoroff A, Halevy S, Bowes-Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction patter. J Cutan Pathol. 2001;28:113-119.
66. Cohen A, Bonneh D, Reuveni H, et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol. 2005;85:299-303.
67. Grau R. Drug-induced psoriasis-A retrospective chart review performed at the University of Oklahoma Department of Dermatology. J Am Acad Dermatol. 2008;59:P2647.
68. Ellis CN, Fallon JD, Heezen JL, et al. Topical indomethacin exacerbates lesions of psoriasis. J Invest Dermatol. 1983;80:362.
69. Cohen AD, Bonneh DY, Reuveni M, et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol. 2005;85:299-303.
70. Chang YC, Wu WM, Chen CH, et al. Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan. Br J Dermatol. 2007;156:642-645.
71. Naranjo CA, Busto U, Seller EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.